Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)
Imunologia e AlergiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The journal of allergy and clinical immunology. In practice
- Publicado em
- 27 fev 2025
- Citações
- 7
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)
Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, Dareen Siri, Roxanne C Oriel, Terri F Brown-Whitehorn, Sara Anvari, William E Berger, J Andrew Bird, Edmond S Chan et al.
Descritores MeSH
- Allergens
- Desensitization, Immunologic
- Peanut Hypersensitivity
- Double-Blind Method
- Administration, Cutaneous
- Humans
- Male
- Arachis
- Treatment Outcome
- Female
Veja também
Estudos relacionados
- From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy-A Systematic Review and Meta-Analysis
- Oral Peanut Immunotherapy With Butyrate Adjuvant (OPIA) in Children: A Randomised, Controlled Trial
- Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities
- Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE